MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, April 2, 2009

MS Trial Alert: Study of Oral Cladribine Added on to Interferon Therapy Recruiting Worldwide

April 1, 2009

Summary: Investigators at approximately 30 sites in the United States and others nationwide are studying the safety and tolerability of oral cladribine (EMD Serono Inc.) compared to placebo as an add-on therapy to injectable interferon beta-1a therapy – Rebif® (EMD Serono and Pfizer), Avonex® (Biogen Idec), or Betaseron® (Bayer Healthcare Pharmaceuticals) – in people with active MS. A total of 200 people are expected to enroll in this study. EMD Serono Inc. is sponsoring this study.

Rationale: Cladribine can interfere with the activity of white blood cells that underlie the immune attacks that cause the unpredictable symptoms of MS. Injectable cladribine has been used to treat hairy cell leukemia. Studies have suggested a potential benefit in people with certain types of MS. Cladribine has been designated by the FDA as a “Fast Track Product,” which should expedite its future review.

To review eligibility and further details for this article, click here to continue to the source for this article.


No comments: